Characterization of experimental resin composites with cholesteryl methacrylate organic matrix - Part 2.

OBJECTIVE: The aim of this study was to evaluate the degree of conversion (%), flexural strength (MPa), elastic modulus (GPa), compressive strength (MPa), Knoop microhardness (KHN), post-gel shrinkage (%) and prediction of ideal concentration of cholesteryl methacrylate (CM) in experimental resins. METHODS: Four formulations were manipulated (F): F1, control group, (0 % CM); F2 (15 % CM); F3 (19.8 % CM) and F4 (30 % CM). Bis-GMA and CM percentages were determined using Statistica™ software. For the degree of conversion test, Raman spectroscopy was used. To testing flexural strength, elastic modulus and compressive strength, a universal testing machine was used. For the Knoop microhardness test five indentations were made in each sample. Post-gel shrinkage was determined using the strain gauge method. Statistica™ software processed all data obtained in this study. Results were submitted to one-way ANOVA and Tukey's post hoc tests (α = 0.05). RESULTS: Better performance was observed for F2 (15 % CM) and F3 (19,8 % CM) for degree of conversion, elastic modulus and post-gel shrinkage. For Knoop microhardness F2 (15 % CM), F3 (19,8 % CM) and F4 (30 % CM) showed higher values than F1 (0 % CM). For flexural strength F1 (0 % CM) and F3 (19,8 %) were similar and F4 showed the lowest values and for compressive strength F1 (0 % CM) showed the highest values. For mixture designs analysis data, concentrations ≤ 25 % of CM would provide better results. SIGNIFICANCE: Addition of CM at concentrations lower than 30 % contributed to a significant increase in the degree of conversion, microhardness values, elastic modulus and reduction of post-gel shrinkage.

Novel matrix formulation for resin composite: Chemical and biomechanical characterization - Part 1.

OBJECTIVE: This study aimed to investigate the effects of adding cholesteryl methacrylate (CM) monomer to experimental composite resins and evaluate its impact on polymerization shrinkage force (PSF), Knoop microhardness (KHN), sorption and solubility (SS), vulnerability to spontaneous oxidation (VOE), porosity (BES), viscosity (V), and cross-link density (CLD). CM was synthesized, mixed with varying proportions of Bis-GMA, 70 wt% filler particles, and 40 % TEGDMA. The groups tested were: CM0 (60 % Bis-GMA), CM6 (54 % Bis-GMA/6 % CM), CM12 (48 % Bis-GMA/12 % CM), CM18 (42 % Bis-GMA/18 % CM) and CM24 (36 % Bis-GMA/24 % CM). The PSF was evaluated using a universal testing machine. KHN was measured with a 50 g load for 30 s. SS was determined according to ISO 4049:2009. VOE was measured with a three-electrode system in an electrochemical cell. BES images were obtained using an electron microscope to assess porosity. Viscosity was measured through rheological analysis. CLD was estimated from hardness readings before and after ethanol storage. RESULTS: CM6 (0.34 N) and CM12 (0.34 N) exhibited the lowest PSF values compared to CM0 (0.91 N). For KHN, CM6 (32.03) and CM12 (31.03) had higher values than CM0 (25.83) and were similar to CM18 (29.39) and CM24 (28.64). SS showed no significant differences among the groups. VOE indicated low vulnerability across all groups. CM12 had greater porosity compared to CM0 in BES images. CM0 had the lowest viscosity among the groups. No differences in CLD were observed among CM0, CM12, CM18, and CM24 regarding softening effects. SIGNIFICANCE: Adding CM to Bis-GMA/TEGDMA composite resins can reduce polymerization shrinkage force and increase the initial Knoop microhardness without affecting the other properties studied.

In silico evidence of bitopertin's broad interactions within the SLC6 transporter family.

The Glycine Transporter Type 1 (GlyT1) significantly impacts central nervous system functions, influencing glycinergic and glutamatergic neurotransmission. Bitopertin, the first GlyT1 inhibitor in clinical trials, was developed for schizophrenia treatment but showed limited efficacy. Despite this, bitopertin's repositioning could advance treating various pathologies. This study aims to understand bitopertin's mechanism of action using computational methods, exploring off-target effects, and providing a comprehensive pharmacological profile. Similarity Ensemble Approach (SEA) and SwissTargetPrediction initially predicted targets, followed by molecular modeling on SWISS-MODEL and GalaxyWeb servers. Binding sites were identified using PrankWeb, and molecular docking was performed with DockThor and GOLD software. Molecular dynamics analyses were conducted on the Visual Dynamics platform. Reverse screening on SEA and SwissTargetPrediction identified GlyT1 (SLC6A9), GlyT2 (SLC6A5), PROT (SLC6A7), and DAT (SLC6A3) as potential bitopertin targets. Homology modeling on SwissModel generated high-resolution models, optimized further on GalaxyWeb. PrankWeb identified similar binding sites in GlyT1, GlyT2, PROT, and DAT, indicating potential interaction. Docking studies suggested bitopertin's interaction with GlyT1 and proximity to GlyT2 and PROT. Molecular dynamics confirmed docking results, highlighting bitopertin's target stability beyond GlyT1. The study concludes that bitopertin potentially interacts with multiple SLC6 family targets, indicating a broader pharmacological property.

A novel arylpiperazine derivative (LQFM181) protects against neurotoxicity induced by 3- nitropropionic acid in in vitro and in vivo models.

In the pursuit of novel antioxidant therapies for the prevention and treatment of neurodegenerative diseases, three new arylpiperazine derivatives (LQFM181, LQFM276, and LQFM277) were synthesized through a molecular hybridization approach involving piribedil and butylated hydroxytoluene lead compounds. To evaluate the antioxidant and neuroprotective activities of the arylpiperazine derivatives, we employed an integrated approach using both in vitro (SH-SY5Y cells) and in vivo (neurotoxicity induced by 3-nitropropionic acid in Swiss mice) models. In the in vitro tests, LQFM181 showed the most promising antioxidant activity at the neuronal membrane and cytoplasmic levels, and significant neuroprotective activity against the neurotoxicity induced by 3-nitropropionic acid. Hence, this compound was further subjected to in vivo evaluation, which demonstrated remarkable antioxidant capacity such as reduction of MDA and carbonyl protein levels, increased activities of succinate dehydrogenase, catalase, and superoxide dismutase. Interestingly, using the same in vivo model, LQFM181 also reduced locomotor behavior and memory dysfunction through its ability to decrease cholinesterase activity. Consequently, LQFM181 emerges as a promising candidate for further investigation into its neuroprotective potential, positioning it as a new therapeutic agent for neuroprotection.

Chrysin bonded to ß-d-glucose tetraacetate enhances its protective effects against the neurotoxicity induced by aluminum in Swiss mice.

OBJECTIVES: To evaluate whether the glycosylation of chrysin (CHR) enhances its protective effects against aluminum-induced neurotoxicity. METHODS: To compare the antioxidant, anticholinesterase, and behavioral effects of CHR with its glycosylated form (CHR bonded to ß-d-glucose tetraacetate, denoted as LQFM280), we employed an integrated approach using both in vitro (SH-SY5Y cells) and in vivo (aluminum-induced neurotoxicity in Swiss mice) models. KEY FINDINGS: LQFM280 demonstrated higher antioxidant activity than CHR in both models. Specifically, LQFM280 exhibited the ability to exert antioxidant effects in the cytoplasm of SH-SY5Y cells, indicating its competence in traversing neuronal membranes. Remarkably, LQFM280 proved more effective than CHR in recovering memory loss and counteracting neuronal death in the aluminum chloride mice model, suggesting its increased bioavailability at the brain level. CONCLUSIONS: The glycosylation of CHR with ß-d-glucose tetraacetate amplifies its neuroprotective effects, positioning LQFM280 as a promising lead compound for safeguarding against neurodegenerative processes involving oxidative stress.